Suppr超能文献

在稳定表达人B2缓激肽受体的中国仓鼠卵巢细胞中对缓激肽受体的功能研究。

Functional studies of bradykinin receptors in Chinese hamster ovary cells stably expressing the human B2 bradykinin receptor.

作者信息

Zhang S P, Wang H Y, Lovenberg T W, Codd E E

机构信息

Drug Discovery Research, R.W. Johnson Pharmaceutical Research Institute, Welsh and McKean Roads, Spring House, PA 19477-0776, USA.

出版信息

Int Immunopharmacol. 2001 May;1(5):955-65. doi: 10.1016/s1567-5769(01)00032-7.

Abstract

Bradykinin B1 and B2 receptors, members of the G-protein coupled receptor superfamily, are involved in inflammation and pain. Chinese hamster ovary (CHO) cells stably expressing the human B2 bradykinin receptor (CHO-B2) were used to characterize the signal transduction pathways associated with this receptor and its regulation. The selective B2 antagonist [3H]NPC17731 but not the selective B1 antagonist [3,4-prolyl-3,4-(3)H(N)]-[des-Arg10,Leu9]kallidin ([3H]DALKD) bound to CHO-B2 cell membranes with a Kd of 0.77 nM and a Bmax of 1087 fmol/mg protein. [3H]NPC17731 binding was inhibited by bradykinin ligands in the order: NPC17731 > bradykinin > kallidin >> DALKD > [des-Arg10] kallidin (DAKD), consistent with the pharmacological profile of B2 bradykinin receptors. The B2 agonist bradykinin and the B1/B2 agonist kallidin, but not the B1 agonist DAKD, increased [35S]GTP gamma S binding to the CHO-B2 cell membranes. The B2 bradykinin receptors were co-immunoprecipitated with G alpha q/11. In response to bradykinin stimulation, coupling of the B2 receptors to G alpha q/11 was increased by 10-fold. Bradykinin and kallidin, but not DAKD, induced intracellular calcium release in CHO-B2 cells, which was blocked by NPC17731 but not by DALKD. These results demonstrate that B2 bradykinin receptors directly coupled to G alpha q/11 to regulate intracellular calcium release. CHO-B2 cell is a useful system that can be applied to study the effect of potential agents that may influence the B2 receptor function.

摘要

缓激肽B1和B2受体属于G蛋白偶联受体超家族成员,参与炎症和疼痛过程。利用稳定表达人B2缓激肽受体的中国仓鼠卵巢(CHO)细胞(CHO - B2)来表征与此受体相关的信号转导途径及其调控。选择性B2拮抗剂[3H]NPC17731能与CHO - B2细胞膜结合,解离常数(Kd)为0.77 nM,最大结合量(Bmax)为1087 fmol/mg蛋白,而选择性B1拮抗剂[3,4 - 脯氨酰 - 3,4 - (3)H(N)] - [去 - Arg10,Leu9]缓激肽([3H]DALKD)则不能。[3H]NPC17731的结合受到缓激肽配体的抑制,抑制顺序为:NPC17731>缓激肽>胰激肽>>DALKD>[去 - Arg10]胰激肽(DAKD),这与B2缓激肽受体的药理学特性一致。B2激动剂缓激肽和B1/B2激动剂胰激肽能增加[35S]GTPγS与CHO - B2细胞膜的结合,而B1激动剂DAKD则不能。B2缓激肽受体与Gαq/11共同免疫沉淀。在缓激肽刺激下,B2受体与Gαq/11的偶联增加了10倍。缓激肽和胰激肽能诱导CHO - B2细胞内钙释放,而DAKD则不能,且这种钙释放被NPC17731阻断,而非DALKD。这些结果表明,B2缓激肽受体直接与Gαq/11偶联以调节细胞内钙释放。CHO - B2细胞是一个有用的系统,可用于研究可能影响B2受体功能的潜在药物的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验